Overview

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Status:
Completed
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.
Phase:
Phase 1
Details
Lead Sponsor:
Taro Pharmaceuticals USA
Treatments:
Clindamycin
Clindamycin palmitate
Clindamycin phosphate